Katja Kiseljak‐Vassiliades

This study identifies glutamine antagonism as a therapeutic strategy for adrenocortical carcinoma by inhibiting de novo nucleotide biosynthesis and inducing DNA damage.

This paper identifies DLK1 as a novel immunotherapeutic target in adrenocortical carcinoma, showing it regulates tumor cell plasticity and chemoresistance, and demonstrates the efficacy of a DLK1-targeting antibody-drug conjugate.

This paper identifies DLK1 as a marker of adrenocortical stem/progenitor cells that predicts malignancy in adrenocortical carcinoma and is detectable in patient serum.

The paper shows that tumor-derived glucocorticoids increase ROR1 expression while suppressing T cell activity, and GC-resistant CAR-T cells can overcome this by preserving ROR1 expression in tumor cells.

This study uses spatial transcriptomics to analyze human adrenal tissue, supporting the centripetal differentiation model and characterizing aldosterone-producing micronodules.